Cencora, Inc. Set to Report Strong Earnings Growth in Q2 2025
With a market cap of $54.8 billion, Cencora, Inc. (COR) is a prominent player in the global healthcare solutions market. The firm is based in Conshohocken, Pennsylvania, and focuses on the sourcing and distribution of pharmaceutical products and healthcare supplies. Cencora provides a variety of services within the healthcare sector, both in the United States and internationally.
Upcoming Fiscal Q2 2025 Earnings
The prescription drug distributor is preparing to release its fiscal Q2 2025 earnings results before the market opens on Wednesday, May 7. Analysts anticipate that COR will report an adjusted EPS of $4.07, representing a 7.1% increase from last year’s $3.80 in the same quarter. Notably, Cencora has outperformed Wall Street’s earnings expectations for the last four quarters.
Financial Outlook for Fiscal 2025
For fiscal 2025, analysts project an adjusted EPS of $15.41 for Cencora, which would be a nearly 12% rise from $13.76 in fiscal 2024.
Stock Performance Compared to Benchmarks
Over the past year, COR has returned 18.7%, significantly outperforming the S&P 500 Index’s ($SPX) 8.2% gain and the Health Care Select Sector SPDR Fund’s (XLV) 2.5% decline.
Recent Financial Results and Adjustments
Cencora’s shares saw a slight rebound on February 5, following the reported Q1 2025 adjusted EPS of $3.73 and revenue of $81.5 billion, both surpassing expectations. The Healthcare Solutions segment was a key contributor to this strong performance, generating $74 billion in revenue driven by high demand for GLP-1 drugs and specialty medications. Additionally, Cencora raised its fiscal 2025 adjusted EPS guidance to a range of $15.25 – $15.55 after completing the $4.6 billion acquisition of Retina Consultants of America (RCA), which has further boosted investor confidence.
Analysts’ Ratings and Price Targets
Among analysts, Cencora holds a favorable consensus rating of “Strong Buy.” Out of 15 analysts covering the stock, 11 have issued “Strong Buy” recommendations while four suggest a “Hold.” The average price target for COR is set at $298.93, indicating a potential upside of approximately 5.9% from its current trading level.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
